Domain Associates

Nobias Therapeutics is a developer of rare pediatric disease drugs intended to cure rare illnesses in children. It focuses on discovering the genetic basis for rare diseases and develops drugs that can intervene in the affected pathways, enabling parents to help their infants become healthier.

WindMIL Therapeutics, Inc. is a biotechnology company that specializes in developing innovative cell therapies for cancer patients, focusing on insights from bone marrow immunology. Established in 2015 and based in Princeton, New Jersey, the company utilizes its proprietary platform to create a new class of therapies known as Marrow Infiltrating Lymphocytes (MILs). These therapies are derived from memory T cells located in the bone marrow, aiming to provide life-saving treatment options for individuals battling cancer.

Tobira Therapeutics, Inc., a biotechnology company, engages in the research, discovery, acquisition, development, and commercialization of antiviral compounds for the treatment of life-threatening and life-altering infectious diseases. It develops TBR-652 and TBR-220 antagonists for the treatment of HIV/AIDS, hepatitis, and other associated infectious conditions. The company was founded in 2006 and is based in Princeton, New Jersey.

Celator Pharmaceuticals, Inc., a biopharmaceutical company, develops therapies to treat cancer. The company focuses on CombiPlex, a drug ratio technology platform that enables to the development of combination therapies. Its products include CPX-1 (Irinotecan HCI-Floxuridine), a treatment for colorectal cancer; and CPX-351 (Cytarabine-Daunorubicin), a treatment for acute myeloid leukemia (AML). Celator Pharmaceuticals, Inc. was formerly known as Celator Technologies, Inc. The company was founded in 2000 and is headquartered in Princeton, New Jersey.

Celator Pharmaceuticals, Inc., a biopharmaceutical company, develops therapies to treat cancer. The company focuses on CombiPlex, a drug ratio technology platform that enables to the development of combination therapies. Its products include CPX-1 (Irinotecan HCI-Floxuridine), a treatment for colorectal cancer; and CPX-351 (Cytarabine-Daunorubicin), a treatment for acute myeloid leukemia (AML). Celator Pharmaceuticals, Inc. was formerly known as Celator Technologies, Inc. The company was founded in 2000 and is headquartered in Princeton, New Jersey.

Celator Pharmaceuticals, Inc., a biopharmaceutical company, develops therapies to treat cancer. The company focuses on CombiPlex, a drug ratio technology platform that enables to the development of combination therapies. Its products include CPX-1 (Irinotecan HCI-Floxuridine), a treatment for colorectal cancer; and CPX-351 (Cytarabine-Daunorubicin), a treatment for acute myeloid leukemia (AML). Celator Pharmaceuticals, Inc. was formerly known as Celator Technologies, Inc. The company was founded in 2000 and is headquartered in Princeton, New Jersey.

Tobira Therapeutics, Inc., a biotechnology company, engages in the research, discovery, acquisition, development, and commercialization of antiviral compounds for the treatment of life-threatening and life-altering infectious diseases. It develops TBR-652 and TBR-220 antagonists for the treatment of HIV/AIDS, hepatitis, and other associated infectious conditions. The company was founded in 2006 and is based in Princeton, New Jersey.

Esprit Pharma is a pharmaceutical company focused on specialty therapeutics and committed to improving patient well-being in the urology and OB/GYN areas by providing products that contribute to bettering patient outcomes.

Esprit Pharma is a pharmaceutical company focused on specialty therapeutics and committed to improving patient well-being in the urology and OB/GYN areas by providing products that contribute to bettering patient outcomes.

Esprit Pharma is a pharmaceutical company focused on specialty therapeutics and committed to improving patient well-being in the urology and OB/GYN areas by providing products that contribute to bettering patient outcomes.

Celator Pharmaceuticals, Inc., a biopharmaceutical company, develops therapies to treat cancer. The company focuses on CombiPlex, a drug ratio technology platform that enables to the development of combination therapies. Its products include CPX-1 (Irinotecan HCI-Floxuridine), a treatment for colorectal cancer; and CPX-351 (Cytarabine-Daunorubicin), a treatment for acute myeloid leukemia (AML). Celator Pharmaceuticals, Inc. was formerly known as Celator Technologies, Inc. The company was founded in 2000 and is headquartered in Princeton, New Jersey.

OraPharma is a specialty pharmaceutical company that develops and commercializes products that help improve and maintain oral health. They are dedicated to delivering scientifically and technologically advanced products to dental professionals and their practices. ARESTIN® (minocycline HCl) Microspheres, 1 mg is a locally administered antibiotic (LAA) offering a patented microsphere technology. OraPharma is proud to have introduced this revolutionary approach to treating periodontitis as an adjunct to scaling and root planing and continues to take a leadership role in educating clinicians and consumers on the disease. Read more about ARESTIN® or click here for Prescribing Information.

NPS Pharmaceuticals, Inc., a biopharmaceutical company, provides therapeutic products for the treatment of gastrointestinal and endocrine disorders. The company offers Gattex for the treatment of adult patients with short bowel syndrome (SBS) who are dependent on parenteral support in the United States; and Revestive for the treatment of adult patients with SBS in the European Union. Its products also include Gattex/Revestive in pediatric SBS, which has completed an open-label 4-cohort study; Natpara, a bioengineered replica of human parathyroid hormone to control hypocalcemia in patients with hypoparathyroidism; and Natpar to treat hypoparathyroidism, as well as NPSP795, a calcilytic agent, which is in Phase IIA clinical stage for treating disorders involving increased calcium receptor activity. In addition, the company offers various royalty-based products, such as Sensipar and Mimpara for the treatment of primary and secondary hyperparathyroidism; Sensipa for treating hypercalcemia in parathyroid cancer; REGPARA for the treatment of secondary hyperparathyroidism; NUCYNTA and Nucynta ER for treating acute pain and chronic pain; and Ronacaleret that is in phase II clinical stage for treating stem cell mobilization. It has collaborations and license agreements with Amgen Inc., GlaxoSmithKline, Kyowa Hakko Kirin, Takeda GmbH, Janssen Pharmaceuticals, Inc., and Hoffman-La Roche Inc. and F. Hoffmann-La Roche Ltd. The company was founded in 1986 and is based in Bedminster, New Jersey. As of February 21, 2015, NPS Pharmaceuticals, Inc. operates as a subsidiary of Shire Pharmaceutical Holdings Ireland Limited.

Genta Incorporated is a biopharmaceutical company focused on the identification, development and commercialization of drugs for the treatment of people with cancer. Genta has built a broad portfolio of proprietary products in various stages of clinical development. The Company’s drugs include Ganite (gallium nitrate injection), tesetaxel, and oral gallium.